"uuid:ID","description","text","instanceType","name","id","label"
"911e8785-8aed-4065-b2f3-dabadab48ce4","Main objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective","OBJ1","Objective_1",""
"a80ee871-de85-4deb-9e2d-e802c30d31d5","Safety","To document the safety profile of the xanomeline TTS.","Objective","OBJ2","Objective_2",""
"8f51ec43-7fc8-4eb6-a942-9560aab631b1","Behaviour","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective","OBJ3","Objective_3",""
"9f69f90b-3a83-402d-9e4e-088908269f97","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective","OBJ4","Objective_4",""
"a3b0a314-5b64-4ac2-8aa2-23839e36bade","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective","OBJ5","Objective_5",""
"525de24a-8e91-40f6-be49-ed6daead43bf","","To assess the treatment response as a function of Apo E genotype.","Objective","OBJ6","Objective_6",""
